ECM
KRYS icon

Everence Capital Management’s Krystal Biotech KRYS Stock Holding History

Everence Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Buy
892
+92
+12% +$27.5K 0.02% 590
2026
Q1 		$207K Buy
+800
New +$213K 0.01% 747
2024
Q4 		– Sell
-3,060
Closed -$557K – 936
2024
Q3 		$557K Buy
+3,060
New +$590K 0.04% 395

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Everence Capital Management's KRYS Position: Q2 2026 in Review

Everence Capital Management increased its Krystal Biotech (KRYS) stake by 12% in Q2 2026, buying an estimated $27.5K and bringing the position to 892 shares worth $332K. The position accounts for 0.02% of the portfolio, ranked #590.

Everence Capital Management first reported a position in KRYS in Q3 2024 and has held it in 3 quarters since. The position peaked at $557K in Q3 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Everence Capital Management held 892 shares of Krystal Biotech worth $332K as of Q2 2026.
  • Everence Capital Management bought 92 Krystal Biotech shares in Q2 2026, an estimated $27.5K.
  • Krystal Biotech made up 0.02% of Everence Capital Management's portfolio in Q2 2026, its #590 holding.
  • Everence Capital Management first reported a position in Krystal Biotech in Q3 2024 and has held it in 3 quarters since.
  • Everence Capital Management's Krystal Biotech position peaked at $557K in Q3 2024.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.